+139.7%
OKLO vs GSK
+58.3%
+81.4%
-89.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.2% | +0.5% | -2.7% | -2.2% |
| 7D | +1.6% | +1.1% | +0.4% | +1.6% |
| 30D | -17.6% | +6.3% | -24.0% | -17.5% |
| 3M | -48.5% | +1.8% | -50.3% | -48.4% |
| 6M | -65.7% | +1.7% | -67.3% | -65.6% |
| YTD | -66.7% | +6.5% | -73.2% | -66.4% |
| 1Y | -76.5% | +9.5% | -86.0% | -76.3% |
| 3Y | +132.5% | +65.3% | +67.2% | +131.0% |
| 5Y | +142.8% | +43.7% | +99.1% | +141.8% |
| All | +139.7% | +58.3% | +81.4% | +136.7% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling